Medicare drug price negotiation is the Inflation Reduction Act process for setting maximum prices on Medicare's costliest medicines, ending the prohibition that dated to 2003. The first ten Part D drugs were selected in August 2023 under the IRA, prices announced in August 2024, effective January 1, 2026; CMS projects $6 billion in savings had those prices applied in 2023.
The program is the largest change in federal drug policy since the Part D benefit was created in 2003, and it works less like a market negotiation and more like a statutory formula with negotiating room at the edges. That design was deliberate: drafters wanted outcomes predictable enough to score and enforceable enough to survive the litigation everyone knew would follow. Manufacturers of selected drugs must participate or face escalating excise taxes — up to 95 percent of a drug's sales — and the price is capped between a ceiling set by formula and a floor related to the drug's net price. This explainer walks through the selection criteria, the negotiation sequence, the enforcement teeth, and what the first round's published results do and do not prove.
How are drugs selected for negotiation?
By spending rank, mechanically. Each year CMS ranks drugs by Medicare spending and selects a statutory number: ten Part D drugs for the first cycle, fifteen more for the second, fifteen more for the third, and twenty per year thereafter — with Part B physician-administered drugs entering the cycle from 2028. Selection is by spending rank, and the schedule stretches into the 2030s, with twenty drugs added per cycle at maturity. Selection rules exclude small-molecule drugs younger than nine years from approval and biologics younger than thirteen, a negotiated industry concession meant to preserve the patent-protected period; drugs with generic or biosimilar competition are also excluded, on the theory that the market already disciplines their prices. The first list, announced August 29, 2023, read like a cardiology and immunology formulary: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and NovoLog, drugs that together accounted for some $56 billion in Part D spending in 2022.
What happens in the negotiation itself?
CMS sends the manufacturer a written offer anchored to a statutory ceiling — a percentage of non-federal average manufacturer price, tied to how long the drug has been on the market — supported by a published calculation of the drug's benefit to Medicare patients. The manufacturer submits offers and data, and CMS may hold meetings and exchange written offers before setting the maximum fair price, which cannot exceed the statutory ceiling. The negotiation is one-to-many on paper and one-on-one in practice: each drug is negotiated separately, and the results are secret until CMS publishes them. For the first round, negotiated prices were announced August 15, 2024, all below list price, with the stated comparison showing discounts ranging from 38 percent to 79 percent off 2023 list prices for 2023 beneficiaries' usage.
Related stories: Getting a Federal Disaster Declaration · Why the Highway Trust Fund Runs Dry.
What forces a manufacturer to show up?
Two enforcement mechanisms. First, the excise tax: a manufacturer that refuses to negotiate or fails to deliver the negotiated price owes a penalty starting at 186 percent of a drug's US sales, escalating to 95 percent of total sales — economically a forced exit from Medicare, since no product survives that margin structure. Second, the alternative: a manufacturer can withdraw all its drugs from Medicare and Medicaid entirely, a step no manufacturer of the selected blockbusters took. The first group of manufacturers challenged the program in multiple federal courts on First Amendment and takings grounds through 2023 and 2024; courts rejected preliminary injunctions in the early cases, and the program proceeded on schedule into 2025.
What else did the IRA change about drug prices?
The negotiation program is the headline, but two other provisions touch more people directly. The law capped Part D out-of-pocket costs at $2,000 per year starting in 2025, replacing the prior coverage-gap structure that had exposed beneficiaries to unlimited cost sharing. It required manufacturers to pay rebates when their drug prices rise faster than inflation across Medicare — a provision already generating rebates since 2022 for Part B and 2023 for Part D. And it capped insulin copays at $35 per month for Part D beneficiaries. The out-of-pocket cap was projected by CMS to save tens of millions of beneficiaries money at the pharmacy counter immediately, independent of the negotiation results.
How does the second round differ?
The second negotiation cycle, announced with fifteen Part D drugs in January 2025 for prices effective 2027, tested the program at scale: more drugs, more manufacturers, and for the first time several therapies whose manufacturers had been prominent in the litigation. CMS also published more process detail the second time — the negotiation timelines, the data elements required from manufacturers, and the patient-verification surveys that feed the clinical-benefit calculation — narrowing the discretion that first-round participants had complained was unreviewable. The statutory schedule from here is fixed: fifteen more drugs for 2028, twenty per year after, with Part B drugs entering the selection pool alongside. The program's design converts a negotiation exercise into a permanent feature of the pharmaceutical market's expected-value math. Every launch price now carries that future selection risk inside it.
What does the first round actually prove?
It proves the machinery works on schedule; it does not yet prove anything about innovation or drug availability, the central arguments on each side. Manufacturers warned during the litigation that negotiation would deter research investment, and some pipeline exits have been announced as portfolio decisions; program defenders answer that the selected drugs are years past patent expiry and that the negotiated prices still exceed manufacturers' net prices after existing rebates. The observable test arrives through 2026: whether any selected drug is withdrawn from Medicare, whether launch prices of new drugs adjust upward in anticipation of future selection, and whether the selection lists year by year capture the newest blockbusters as their statutory exclusions lapse. Those data points, not the 2024 press releases, will settle what the program changes.